Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
Ulrike Leiter, Rudolf Stadler, Cornelia Mauch et al. · The Lancet Oncology · 2016
Cited by 707 works. doi:10.1016/s1470-2045(16)00141-8
Authors
- Ulrike Leiter
- Rudolf Stadler
- Cornelia Mauch
- Werner Hohenberger
- Norbert H. Brockmeyer
- Carola Berking
- Cord H. Sunderkötter
- Martin Kaatz
- K.W. Schulte
- Percy M. Lehmann
- THOMAS M. VOGT
- Jens Ulrich
- Rudolf Alexander Herbst
- Wolfgang Gehring
- Jan‐Christoph Simon
- Ulrike Keim
- Peter Martus
- Claus Garbe
References
- Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
- Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis
- Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the Limbs
- Sentinel-Node Biopsy or Nodal Observation in Melanoma
- Efficacy of an Elective Regional Lymph Node Dissection of 1 to 4 mm Thick Melanomas for Patients 60 Years of Age and Younger
- Validation of the Accuracy of Intraoperative Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma
- Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial
- Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
- Efficacy of Elective Lymph Node Dissection in Patients with Intermediate Thickness Primary Melanoma
- Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial